Depression - Atypical lifecycle management strategy rejuvenates depression market

Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.

Sales of atypical antipsychotics in depression are set to be stimulated by anticipated positive clinical trial data investigating the use of Seroquel (quetiapine) in this indication. Datamonitor forecasts peak class level seven major market sales of $1.43 billion in 2008, followed by a decline due to competition from pipeline drugs and generics.

Timing of launch of Wyeth's reformulation Pristiq (desvenlafaxine) would appear to be optimal. However, no evidence exists to indicate that it is an improvement over the parent compound Effexor (venlafaxine). By focusing Pristiq on a niche cohort of depressed patients, Wyeth has done enough to diversify Pristiq to ensure moderate success.

The introduction of newer generation antidepressants such as the SNRIs Effexor and Cymbalta (duloxetine) and the SSRI Lexapro (escitalopram) into the Japanese depression market will drive its value considerably, resulting in a 52% increase by 2012.

Read more...

• Type 1 Diabetes (28/06/2010)
• Parkinson’s Disease (28/06/2010)
• Pulmonary Arterial Hypertension (28/06/2010)

• Insomnia (21/05/2008)
• Multiple Sclerosis (21/05/2008)
• Top 20 Cancer Therapy Brands (20/05/2008)
• Disease Management and Drug Adherence (20/05/2008)
• Asthma & COPD (20/05/2008)
• HIV (20/05/2008)
• Upper GI Disorders (20/05/2008)
• Antidyslipidemics (20/05/2008)
• Antihypertensives (20/05/2008)

---